Expression of α-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium

Human Pathology

Volumn 37, Issue 12, 2006, Pages 1601-1606

  Lisovsky, Mikhail ^a,b   Falkowski, Olga ^a,b   Bhuiya, Tawfiqul ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Dysplasia; High grade; Racemase; Reactive atypia

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE;

ADULT; ARTICLE; BARRETT ESOPHAGUS; BIOPSY; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

AGED; BARRETT ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RACEMASES AND EPIMERASES;

EID: 33751208046     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.06.009     Document Type: Article

References (33)

1. Bronner M.P. Inflammatory disorders of the esophagus. In: Odze R.D., Goldblum J.R., and Crawford J.M. (Eds). Surgical pathology of the GI tract, liver, biliary tract, and pancreas (2004), Elsevier, Philadelphia (Pa) 121-142
2. Goldblum J.R., and Lauwers G.Y. Dysplasia arising in Barrett's esophagus: diagnostic pitfalls and natural history. Semin Diagn Pathol 19 (2002) 12-19
3. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 1028-1032
4. Reid B.J., Haggitt R.C., Rubin C.E., et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19 (1988) 166-178
5. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676
6. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 120 (2001) 1630-1639
7. Brown L.M., and Devesa S.S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 11 (2002) 235-256
8. Spechler S.J. Dysplasia in Barrett's esophagus: limitations of current management strategies. Am J Gastroenterol 100 (2005) 927-935
9. Bergman J.J. Diagnosis and therapy of early neoplasia in Barrett's esophagus. Curr Opin Gastroenterol 21 (2005) 466-471
10. Wanders R.J., Vreken P., Ferdinandusse S., et al. Peroxisomal fatty acid alpha- and beta-oxidation in humans: enzymology, peroxisomal metabolite transporters and peroxisomal diseases. Biochem Soc Trans 29 (2001) 250-267
11. Schmitz W., Fingerhut R., and Conzelmann E. Purification and properties of an alpha-methylacyl-CoA racemase from rat liver. Eur J Biochem 222 (1994) 313-323
12. Jiang Z., Fanger G.R., Woda B.A., et al. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: a study of 761 cases. Hum Pathol 34 (2003) 792-796
13. Witkiewicz A.K., Varambally S., Shen R., et al. Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. Cancer Epidemiol Biomark Prev 14 (2005) 1418-1423
14. Chen Z.M., Ritter J.H., and Wang H.L. Differential expression of alpha-methylacyl coenzyme a racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol 29 (2005) 890-896
15. Jiang Z., Fanger G.R., Banner B.F., et al. A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma. Cancer Detect Prev 27 (2003) 422-426
16. Jiang Z., Woda B.A., Rock K.L., et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25 (2001) 1397-1404
17. Zhou M., Chinnaiyan A.M., Kleer C.G., Lucas P.C., and Rubin M.A. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 26 (2002) 926-931
18. Wu C.L., Yang X.J., Tretiakova M., et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 35 (2004) 1008-1013
19. Kumar-Sinha C., Shah R.B., Laxman B., et al. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol 164 (2004) 787-793
20. Jiang Z., Woda B.A., Wu C.L., and Yang X.J. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol 122 (2004) 275-289
21. Montgomery E., Goldblum J.R., Greenson J.K., et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 (2001) 379-388
22. Krishnadath K.K., Reid B.J., and Wang K.K. Biomarkers in Barrett esophagus. Mayo Clin Proc 76 (2001) 438-446
23. Dorer R.K., Glickman J.N., Blount P.L., Ayub K., Reid B., and Odze R.D. Immunostaining for AMACR is useful in distinguishing reactive from dysplastic epithelium in Barrett's esophagus and inflammatory bowel disease. Mod Pathol 18 Suppl 1 (2005) 102A
24. Reid B.J., Blount P.L., and Rabinovitch P.S. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 (2003) 369-397
25. Younes M., Lebovitz R.M., Lechago L.V., and Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105 (1993) 1637-1642
26. Jones D.R., Davidson A.G., Summers C.L., Murray G.F., and Quinlan D.C. Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 57 (1994) 598-603
27. Krishnadath K.K., Tilanus H.W., van Blankenstein M., Bosman F.T., and Mulder A.H. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 175 (1995) 175-180
28. Hamelin R., Flejou J.F., Muzeau F., et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107 (1994) 1012-1018
29. Coggi G., Bosari S., Roncalli M., et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79 (1997) 425-432
30. Bani-Hani K., Martin I.G., Hardie L.J., et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92 (2000) 1316-1321
31. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96 (2001) 2839-2848
32. Rabinovitch P.S., Longton G., Blount P.L., Levine D.S., and Reid B.J. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96 (2001) 3071-3083
33. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95 (2000) 1669-1676